LAG3 and renal cell carcinoma: The STELLAR-002 trial (NCT05176483) aims to assess the activity of a new multi-targeted inhibitor of receptor tyrosine kinases, XL092, in combination with many immunotherapy agents, such as the anti-LAG3 relatlimab, in unresectable advanced solid tumors, including RCC.